Your browser doesn't support javascript.
loading
Acute generalized exanthematous pustulosis: European expert consensus for diagnosis and management.
Tetart, F; Walsh, S; Milpied, B; Gaspar, K; Vorobyev, A; Tiplica, G S; Didona, B; Welfringer-Morin, A; Kucinskiene, V; Bensaid, B; Marvanova, E; Salavastru, C; Brezinova, E; Chua, S L; Lovgren, M L; Hammers, C M; Barbaud, A; Mortz, C G; Horvath, B; Meyersburg, D; Lebrun-Vignes, B; Bodemer, C; Brüggen, M C; French, L E; Ingen-Housz-Oro, S.
Afiliação
  • Tetart F; Department of Dermatology and Allergology, Charles Nicolle University Hospital, Rouen, France.
  • Walsh S; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
  • Milpied B; Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL Reference Center, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Gaspar K; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
  • Vorobyev A; Department of Dermatology, King's College Hospital, London, UK.
  • Tiplica GS; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
  • Didona B; Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL Reference Center, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Welfringer-Morin A; Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France.
  • Kucinskiene V; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
  • Bensaid B; Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Marvanova E; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
  • Salavastru C; Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
  • Brezinova E; Department of Dermatology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
  • Chua SL; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
  • Lovgren ML; Department of Dermatology II, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Hammers CM; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
  • Barbaud A; Center of Rare Diseases IDI-IRCCS-Rome, Rome, Italy.
  • Mortz CG; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
  • Horvath B; Department of Dermatology, Necker-Enfants Malades University Hospital, Paris, France.
  • Meyersburg D; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
  • Lebrun-Vignes B; Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences (LUHS), Hospital of LUHS Kauno Klinikos, Kaunas, Lithuania.
  • Bodemer C; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
  • Brüggen MC; Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL Reference Center, AP-HP, Henri Mondor Hospital, Créteil, France.
  • French LE; Department of Dermatology, Edouard Herriot University Hospital, Lyon, France.
  • Ingen-Housz-Oro S; Department of Dermatovenereology, Faculty of Medicine, St. Ann's University Hospital, Masaryk University, Brno, Czech Republic.
Article em En | MEDLINE | ID: mdl-39023187
ABSTRACT
Acute generalized exanthematous pustulosis (AGEP) is a rare, usually drug-induced, acute pustular rash. Despite the lack of strong data supporting the effectiveness of topical or systemic corticosteroids in this drug reaction, they are widely used. More generally, there is no consensus on the diagnostic modalities and the management of patients with AGEP. We aimed to provide European expert recommendations for the diagnosis and management or patients with AGEP. Members of the ToxiTEN group of the European Reference Network (ERN)-skin, all dermatologists and/or allergologists with expertise in drug reactions, elaborated these recommendations based on their own experience and on a review of the literature. Recommendations were separated into the following categories professionals involved, assessment of the diagnosis of AGEP, management of the patient and allergological work-up after the acute phase. Consensus was obtained among experts for the list of professionals involved for the diagnosis and management of AGEP, including the minimum diagnostic work-up, the setting of management, the treatments, the modalities and the timing of allergological work-up and follow-up. European experts in drug allergies propose herein consensus on the diagnosis and management of patients with AGEP. A multidisciplinary approach is warranted, including dermatologists, allergologists and pharmacovigilance services.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article